Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128


Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis.

Lu J, Lu J, Chen W, Huo Y, Huang X, Hou J; Chinese Medical Doctor Association Hematology Branch.

Blood Cancer J. 2014 Aug 15;4:e239. doi: 10.1038/bcj.2014.55.


More frequent IgD and reduced CD200 expression in Chinese patients younger than 50 years old with multiple myeloma: a multicenter analysis.

Lu J, Lu J, Chen W, Wang J, Huo Y, Hou J, Huang X.

Drug Des Devel Ther. 2016 Nov 8;10:3673-3679. eCollection 2016.


International Staging System predicts prognosis of Chinese patients with multiple myeloma across different calendar periods with application of novel agents.

Yang SH, Teng HW, Hong YC, Liu CY, Yu YB, Yang CF, Gau JP, Liu JH, Chang TJ, Yen JJ, Chen PM, Chiou TJ, Tzeng CH, Hsiao LT.

Ann Hematol. 2012 Jan;91(1):93-102. doi: 10.1007/s00277-011-1251-y. Epub 2011 May 17.


Analysis of clinical features, treatment response, and prognosis among 61 elderly newly diagnosed multiple myeloma patients: a single-center report.

An N, Li X, Shen M, Chen S, Huang Z.

World J Surg Oncol. 2015 Aug 7;13:239. doi: 10.1186/s12957-015-0649-8.


Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study.

Oh S, Koo DH, Kwon MJ, Kim K, Suh C, Min CK, Yoon SS, Shin HJ, Jo DY, Kwak JY, Kim JS, Sohn SK, Joo YD, Eom HS, Kim SH, Kim YS, Kim C, Mun YC, Kim H, Lee DS, Lee JH; Korean Multiple Myeloma Working Party (KMMWP).

Ann Hematol. 2014 Aug;93(8):1353-61. doi: 10.1007/s00277-014-2057-5. Epub 2014 Mar 27.


[Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].

Deng SH, Xu Y, Mai YJ, Wang YF, Zhao YZ, Zou DH, Qiu LG.

Zhonghua Xue Ye Xue Za Zhi. 2008 Apr;29(4):217-21. Chinese.


Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy.

Drach J, Ackermann J, Fritz E, Krömer E, Schuster R, Gisslinger H, DeSantis M, Zojer N, Fiegl M, Roka S, Schuster J, Heinz R, Ludwig H, Huber H.

Blood. 1998 Aug 1;92(3):802-9.


[Clinical analysis of newly diagnosed multiple myeloma patients with renal dysfunction].

Zhu W, Lu J, Lu J, Hou J, Huang X, Chen W.

Zhonghua Yi Xue Za Zhi. 2015 Mar 17;95(10):741-4. Chinese.


Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.

Li F, Xu Y, Deng P, Yang Y, Sui W, Jin F, Hao M, Li Z, Zang M, Zhou D, Gu Z, Ru K, Wang J, Cheng T, Qiu L.

Oncotarget. 2015 Apr 20;6(11):9434-44.


Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.

Grzasko N, Hus M, Pluta A, Jurczyszyn A, Walter-Croneck A, Morawska M, Chocholska S, Hajek R, Dmoszynska A.

Hematol Oncol. 2013 Mar;31(1):41-8. doi: 10.1002/hon.2018. Epub 2012 Jun 6.


Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.

Dimopoulos MA, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Gkotzamanidou M, Iakovaki M, Matsouka C, Mparmparoussi D, Roussou M, Efstathiou E, Terpos E.

Leukemia. 2010 Oct;24(10):1769-78. doi: 10.1038/leu.2010.175. Epub 2010 Aug 26.


[Clinical and cytogenetic characteristics of myeloma patients with overall survival less than 24 months].

Zhuang J, Tang W, Li H, Chen M, Han B, Zhu T, Duan M, Li J, Zhang W, Xu Y, Wang S, Zhao Y, Zhou D.

Zhonghua Yi Xue Za Zhi. 2015 Mar 17;95(10):736-40. Chinese.


Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t(4;14) and overcomes their adverse prognosis.

El-Ghammaz AM, Abdelwahed E.

Ann Hematol. 2016 Aug;95(8):1315-21. doi: 10.1007/s00277-016-2692-0. Epub 2016 May 16.


Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients.

Kim MK, Suh C, Lee DH, Min CK, Kim SJ, Kim K, Moon JH, Yoon SS, Lee GW, Kang HJ, Kim SH, Choi CW, Eom HS, Kwak JY, Kim HJ, Mun YC, Bang SM, Lee K, Shin HJ, Lee JH; Korean Multiple Myeloma Working Party.

Ann Oncol. 2011 Feb;22(2):411-6. doi: 10.1093/annonc/mdq393. Epub 2010 Aug 2.


Predictive role of interphase cytogenetics for survival of patients with multiple myeloma.

Königsberg R, Zojer N, Ackermann J, Krömer E, Kittler H, Fritz E, Kaufmann H, Nösslinger T, Riedl L, Gisslinger H, Jäger U, Simonitsch I, Heinz R, Ludwig H, Huber H, Drach J.

J Clin Oncol. 2000 Feb;18(4):804-12.


Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.

Neben K, Jauch A, Bertsch U, Heiss C, Hielscher T, Seckinger A, Mors T, Müller NZ, Hillengass J, Raab MS, Ho AD, Hose D, Goldschmidt H.

Haematologica. 2010 Jul;95(7):1150-7. doi: 10.3324/haematol.2009.016436. Epub 2010 Mar 10.


[Prognostic value of the new international staging system in multiple myeloma. Comparison with Durie-Salmon staging system].

Conté L G, Figueroa M G, Lois V V, Cabrera C ME, León R A, García L H, Rojas R H.

Rev Med Chil. 2008 Jan;136(1):7-12. doi: /S0034-98872008000100001. Epub 2008 Apr 30. Spanish.


Risk stratification model in elderly patients with multiple myeloma: clinical role of magnetic resonance imaging combined with international staging system and cytogenetic abnormalities.

Song MK, Chung JS, Lee JJ, Lee JH, Song IC, Lee SM, Shin DY, Lee GW, Lee IS.

Acta Haematol. 2015;134(1):7-16. doi: 10.1159/000370235. Epub 2015 Mar 28.


[Investigation of 1q21 amplification in patients with multiple myeloma using I-FISH and cIg-FISH].

Yang RF, Li CM, Qiu HR, Lu H, Wu HX, Xu JR, Zhang P, Li JY, Chen LJ.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2011 Dec;28(6):686-9. doi: 10.3760/cma.j.issn.1003-9406.2011.06.020. Chinese.


Supplemental Content

Support Center